- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Hormone receptor positive (HR+) human epidermal growth factor receptor 2 negative (HER2-) breast cancer
- Meeting Date: November 2023
- Public Summary Document (PSD) November 2023 PBAC Meeting - (PDF 1.4MB)
- Public Summary Document (PSD) November 2023 PBAC Meeting - (Word 769KB)
Abemaciclib – November 2023
Abemaciclib: Tablet 50 mg, Tablet 100 mg, Tablet 150 mg; Verzenio®
Last updated
1 March 2024